India, April 29 -- British drug major AstraZeneca Plc. (AZN.L,AZN) Tuesday announced the recommendation for European Union approval of a fixed-duration Calquence-based regimens to treat chronic lymphocytic leukaemia or CLL. In a separate statement, the company issued an update on CAPItello-280 Phase III trial of Truqap in metastatic castration-resistant prostate cancer or mCRPC.
AstraZeneca said it is discontinuing the CAPItello-280 Phase III trial based on the recommendation of the Independent Data Monitoring Committee or IDMC that the Truqap combination was unlikely to meet the dual primary endpoints.
The trial was evaluating the efficacy and safety of Truqap (capivasertib) in combination with docetaxel and androgen-deprivation therapy ...